Gansevoort, R. T. Et Al. 2016. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. NEPHROLOGY DIALYSIS TRANSPLANTATION , vol.31, no.3 , 337-348.

Gansevoort, R. T., ARICI, M., Benzing, T., Birn, H., Capasso, G., Covic, A., ... Devuyst, O.(2016). Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. NEPHROLOGY DIALYSIS TRANSPLANTATION , vol.31, no.3, 337-348.

Gansevoort, Ron Et Al. "Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice," NEPHROLOGY DIALYSIS TRANSPLANTATION , vol.31, no.3, 337-348, 2016

Gansevoort, Ron T. Et Al. "Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice." NEPHROLOGY DIALYSIS TRANSPLANTATION , vol.31, no.3, pp.337-348, 2016

Gansevoort, R. T. Et Al. (2016) . "Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice." NEPHROLOGY DIALYSIS TRANSPLANTATION , vol.31, no.3, pp.337-348.

@article{article, author={Ron T. Gansevoort Et Al. }, title={Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice}, journal={NEPHROLOGY DIALYSIS TRANSPLANTATION}, year=2016, pages={337-348} }